CAR-T Cells - The Next Era in Immuno-Oncology
In the six short years since FDA approval of the first therapy of the modern era, immuno-oncology (I-O) therapies have garnered FDA approvals in six tumor types, received indications for adjuvant, first-line metastatic and salvage disease, and been combined for dual I-O therapy.
In the next 12-18 months, I-O therapies are likely to receive an additional five tumor type approvals. Key opinion leaders believe that I-O therapies may replace chemotherapy as the backbone of modern cancer treatment. Stakeholder adoption of I-O therapies is no longer a question of “IF” but a question of “When.”
Chimeric antigen receptor (CAR)-T cells are the next frontier in this rapidly growing field. Early clinical trials demonstrate that CAR-T cells produce rapid, complete and durable responses in highly refractory patients, making this therapy a potential game-changer. However, the complexity of CAR-T synthesis and delivery, the need for wrap-around services, timing for approval and the potential reimbursement challenges may impact CAR-T’s potential for commercial success.
In this article, originally published in the American Journal of Managed Care, experts from Cardinal Health Specialty Solutions discuss the efficacy and toxicity of CAR-T from early clinical trial results and evaluate the potential commercial success for this therapy.
March 2017
Industry Insights
Receive monthly Industry Insights in your inbox.
Sign up
Bruce Feinberg, DO
Vice President, Chief Medical OfficerCardinal Health Specialty Solutions
Members login
Become a member
VitalSource™ GPO is a consultative partner who delivers meaningful solutions to make your business more successful.